NTLA250117C7500
- 1.88
- -0.12-6.00%
Intellia Therapeutics Newsroom
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $45
Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $12
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $40 to $45
Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), CareDx (CDNA) and Intellia Therapeutics (NTLA)
Intellia Therapeutics Analyst Ratings
Oppenheimer Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $40
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $50
Analysts' Top Healthcare Picks: Inozyme Pharma (INZY), Intellia Therapeutics (NTLA)
Barclays Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $55
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $29 to $60
Intellia Therapeutics Is Maintained at Overweight by Wells Fargo
Intellia Therapeutics Analyst Ratings
BMO Capital Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $50
Intellia Therapeutics (NTLA) Receives a Buy From Evercore ISI
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $60
Wells Fargo Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $60
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $29
Strategic Realignment and Pipeline Potential Drive Buy Rating for Intellia Therapeutics
RBC Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Cuts Target Price to $47
RBC Cuts Price Target on Intellia Therapeutics to $47 From $54, Keeps Outperform, Speculative Risk